| Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor SR Daigle, EJ Olhava, CA Therkelsen, CR Majer, CJ Sneeringer, J Song, ... Cancer cell 20 (1), 53-65, 2011 | 1008 | 2011 |
| MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L KM Bernt, N Zhu, AU Sinha, S Vempati, J Faber, AV Krivtsov, Z Feng, ... Cancer cell 20 (1), 66-78, 2011 | 949 | 2011 |
| Chromatin-modifying enzymes as modulators of reprogramming TT Onder, N Kara, A Cherry, AU Sinha, N Zhu, KM Bernt, P Cahan, ... Nature 483 (7391), 598, 2012 | 764 | 2012 |
| MLL-rearranged leukemias—an update on science and clinical approaches AC Winters, KM Bernt Frontiers in pediatrics 5, 4, 2017 | 434 | 2017 |
| DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia CW Chen, RP Koche, AU Sinha, AJ Deshpande, N Zhu, R Eng, ... Nature medicine 21 (4), 335, 2015 | 231 | 2015 |
| Human milk as a carrier of biochemical messages KM Bernt, WA Walker Acta Paediatrica 88, 27-41, 1999 | 226 | 1999 |
| A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells S Tuve, H Wang, C Ware, Y Liu, A Gaggar, K Bernt, D Shayakhmetov, ... Journal of virology 80 (24), 12109-12120, 2006 | 185 | 2006 |
| D. 958 Shayakhmetov, Z. Li, R. Strauss, D. Stone, and A. Lieber. 2006. A new 959 group B adenovirus receptor is expressed at high levels on human stem and 960 tumor cells S Tuve, H Wang, C Ware, Y Liu, A Gaggar, K Bernt J Virol 80, 12109-20, 0 | 185* | |
| AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes AJ Deshpande, A Deshpande, AU Sinha, L Chen, J Chang, A Cihan, ... Cancer cell 26 (6), 896-908, 2014 | 184 | 2014 |
| Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l AJ Deshpande, L Chen, M Fazio, AU Sinha, KM Bernt, D Banka, S Dias, ... Blood, blood-2012-11-465120, 2013 | 178 | 2013 |
| Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia KMMD Bernt, SPMD Hunger Frontiers in oncology 4, 54, 2014 | 166 | 2014 |
| A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases P Sova, XW Ren, S Ni, KM Bernt, J Mi, N Kiviat, A Lieber Molecular Therapy 9 (4), 496-509, 2004 | 156 | 2004 |
| Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l L Chen, AJ Deshpande, D Banka, KM Bernt, S Dias, C Buske, EJ Olhava, ... Leukemia 27 (4), 813, 2013 | 149 | 2013 |
| Targeting epigenetic programs in MLL-rearranged leukemias KM Bernt, SA Armstrong ASH Education Program Book 2011 (1), 354-360, 2011 | 129 | 2011 |
| Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons S Ni, K Bernt, A Gaggar, ZY Li, HP Kiem, A Lieber Human gene therapy 16 (6), 664-677, 2005 | 123 | 2005 |
| Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy KM Bernt, S Ni, AT Tieu, A Lieber Cancer research 65 (10), 4343-4352, 2005 | 82 | 2005 |
| Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors KM Bernt, DS Steinwaerder, S Ni, ZY Li, SR Roffler, A Lieber Cancer research 62 (21), 6089-6098, 2002 | 82 | 2002 |
| The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors KM Bernt, S Ni, ZY Li, DM Shayakhmetov, A Lieber Molecular Therapy 8 (5), 746-755, 2003 | 76 | 2003 |
| Leukemia stem cells and human acute lymphoblastic leukemia KM Bernt, SA Armstrong Seminars in hematology 46 (1), 33-38, 2009 | 73 | 2009 |
| Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia E Danis, T Yamauchi, K Echanique, X Zhang, JN Haladyna, SS Riedel, ... Cell reports 14 (8), 1953-1965, 2016 | 70 | 2016 |
